Below is the **fully consolidated taxonomic entity list** derived from all three attached papers (Kumar 2021, Seyhan 2025, Bożyk 2022), integrating previously extracted entities and removing duplication.

Format: **Markdown with checkboxes**, hierarchically organized.

---

# 1. Diseases & Clinical Conditions

## 1.1 Primary Cancers

* [ ] Hepatocellular carcinoma (HCC)
* [ ] Colorectal cancer
* [ ] Lung cancer
* [ ] Breast cancer
* [ ] Pancreatic cancer
* [ ] Gastric cancer
* [ ] Prostate cancer
* [ ] Renal cell carcinoma
* [ ] Melanoma

## 1.2 Liver-Related Conditions

* [ ] Liver cirrhosis
* [ ] Chronic hepatitis
* [ ] Viral hepatitis
* [ ] Hepatitis B virus (HBV) infection
* [ ] Hepatitis C virus (HCV) infection
* [ ] Non-alcoholic fatty liver disease (NAFLD)
* [ ] Non-alcoholic steatohepatitis (NASH)
* [ ] Liver fibrosis

## 1.3 Tumor-Associated Pathological Processes

* [ ] Tumorigenesis
* [ ] Carcinogenesis
* [ ] Metastasis
* [ ] Angiogenesis
* [ ] Immune evasion
* [ ] Chronic inflammation
* [ ] Fibrosis
* [ ] Hypoxia
* [ ] Immunosuppression

---

# 2. Cellular Entities

## 2.1 Tumor Cells

* [ ] Tumor cells
* [ ] Cancer stem cells

## 2.2 Adaptive Immune Cells

* [ ] CD4⁺ T cells

  * [ ] Th1 cells
  * [ ] Th2 cells
  * [ ] Th17 cells
  * [ ] T follicular helper (Tfh) cells
* [ ] CD8⁺ T cells
* [ ] Cytotoxic T lymphocytes (CTLs)
* [ ] Regulatory T cells (Tregs)
* [ ] B cells
* [ ] Plasma cells

## 2.3 Innate Immune Cells

* [ ] Natural killer (NK) cells
* [ ] Natural killer T (NKT) cells
* [ ] Dendritic cells (DCs)
* [ ] Tumor-associated macrophages (TAMs)

  * [ ] M1 macrophages
  * [ ] M2 macrophages
* [ ] Myeloid-derived suppressor cells (MDSCs)
* [ ] Monocytes
* [ ] Neutrophils

  * [ ] Cancer-associated neutrophils (CANs)
* [ ] Mast cells

## 2.4 Stromal & Structural Cells

* [ ] Cancer-associated fibroblasts (CAFs)
* [ ] Hepatic stellate cells
* [ ] Endothelial cells
* [ ] Pericytes
* [ ] Mesenchymal stem cells

---

# 3. Tumor Microenvironment (TME)

## 3.1 Structural Components

* [ ] Tumor microenvironment (TME)
* [ ] Extracellular matrix (ECM)

  * [ ] Collagen
  * [ ] Fibronectin
  * [ ] Laminin
  * [ ] Proteoglycans
* [ ] Stromal compartment
* [ ] Immune infiltrate
* [ ] Hypoxic niche

## 3.2 ECM Remodeling

* [ ] Matrix metalloproteinases (MMPs)

---

# 4. Cytokines & Chemokines

## 4.1 Interleukins

* [ ] IL-1
* [ ] IL-2
* [ ] IL-6
* [ ] IL-10
* [ ] IL-12
* [ ] IL-17
* [ ] IL-23

## 4.2 Other Cytokines & Growth Factors

* [ ] Tumor necrosis factor-alpha (TNF-α)
* [ ] Transforming growth factor-beta (TGF-β)
* [ ] Interferon-gamma (IFN-γ)
* [ ] Vascular endothelial growth factor (VEGF)
* [ ] Granulocyte-macrophage colony-stimulating factor (GM-CSF)

## 4.3 Chemokines

* [ ] CCL2
* [ ] CCL5
* [ ] CXCL8
* [ ] CXCL9
* [ ] CXCL10

---

# 5. Immune Checkpoints & Regulatory Molecules

* [ ] Programmed cell death protein 1 (PD-1)
* [ ] Programmed death-ligand 1 (PD-L1)
* [ ] Programmed death-ligand 2 (PD-L2)
* [ ] Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
* [ ] Lymphocyte activation gene-3 (LAG-3)
* [ ] T cell immunoglobulin and mucin domain-3 (TIM-3)
* [ ] TIGIT
* [ ] Indoleamine 2,3-dioxygenase (IDO)

---

# 6. Molecular & Immunological Entities

## 6.1 Antigen Presentation

* [ ] Antigens
* [ ] Tumor-associated antigens (TAAs)
* [ ] Neoantigens
* [ ] Major histocompatibility complex (MHC)
* [ ] T cell receptor (TCR)
* [ ] B cell receptor (BCR)

## 6.2 Intracellular Signaling Molecules

* [ ] β-catenin
* [ ] STAT3
* [ ] NF-κB

---

# 7. Signaling Pathways

* [ ] JAK/STAT pathway
* [ ] MAPK pathway
* [ ] PI3K/AKT pathway
* [ ] NF-κB pathway
* [ ] Wnt/β-catenin pathway
* [ ] TGF-β signaling pathway
* [ ] VEGF signaling pathway

---

# 8. Immunotherapy Modalities

## 8.1 Immune Checkpoint Inhibitors

* [ ] Anti-PD-1 therapy
* [ ] Anti-PD-L1 therapy
* [ ] Anti-CTLA-4 therapy

## 8.2 Cellular Therapies

* [ ] CAR-T cell therapy
* [ ] TCR-T therapy
* [ ] Adoptive cell transfer (ACT)

## 8.3 Additional Immunotherapies

* [ ] Cancer vaccines
* [ ] Oncolytic virus therapy
* [ ] Combination immunotherapy
* [ ] Targeted therapy
* [ ] Anti-angiogenic therapy

---

# 9. Viral Entities

* [ ] Hepatitis B virus (HBV)
* [ ] Hepatitis C virus (HCV)
* [ ] Oncolytic viruses

Below are **additional entities** extracted from the three papers, expanding beyond the prior taxonomy. These include specific **genes, receptors, transcription factors, surface markers, metabolic mediators, enzymes, biomarkers, and therapeutic agents** explicitly discussed across the documents   

Format maintained: **Markdown with checkboxes**, taxonomically grouped.

---

# 10. Surface Markers & Immune Cell Markers

## 10.1 T Cell Markers

* [ ] CD3
* [ ] CD4
* [ ] CD8
* [ ] CD25
* [ ] FOXP3
* [ ] CD28
* [ ] CD40L
* [ ] ICOS
* [ ] OX40

## 10.2 Myeloid & Macrophage Markers

* [ ] CD11b
* [ ] CD14
* [ ] CD33
* [ ] CD68
* [ ] CD80
* [ ] CD86
* [ ] CD163
* [ ] CD206

## 10.3 NK Cell Markers

* [ ] CD56
* [ ] NKG2D
* [ ] NKp30
* [ ] NKp46

## 10.4 Endothelial & Stromal Markers

* [ ] CD31
* [ ] α-SMA (alpha-smooth muscle actin)
* [ ] FAP (fibroblast activation protein)

---

# 11. Transcription Factors

* [ ] FOXP3
* [ ] STAT1
* [ ] STAT3
* [ ] STAT5
* [ ] NF-κB
* [ ] HIF-1α
* [ ] c-Myc
* [ ] T-bet
* [ ] GATA3
* [ ] RORγt

---

# 12. Metabolic & Hypoxia-Related Entities

* [ ] Hypoxia-inducible factor 1-alpha (HIF-1α)
* [ ] Lactate
* [ ] Adenosine
* [ ] Arginase-1 (ARG1)
* [ ] Inducible nitric oxide synthase (iNOS)
* [ ] Reactive oxygen species (ROS)
* [ ] Glucose transporter 1 (GLUT1)

---

# 13. Adhesion & Co-stimulatory Molecules

* [ ] ICAM-1
* [ ] VCAM-1
* [ ] CD40
* [ ] CD80
* [ ] CD86
* [ ] CD137 (4-1BB)
* [ ] OX40L

---

# 14. Enzymes & Proteases

* [ ] Matrix metalloproteinase-2 (MMP-2)
* [ ] Matrix metalloproteinase-9 (MMP-9)
* [ ] Caspase-3
* [ ] Caspase-8
* [ ] Arginase
* [ ] Cyclooxygenase-2 (COX-2)

---

# 15. Growth Factors & Angiogenic Mediators

* [ ] VEGF-A
* [ ] VEGFR-2
* [ ] Platelet-derived growth factor (PDGF)
* [ ] Epidermal growth factor (EGF)
* [ ] Hepatocyte growth factor (HGF)
* [ ] Fibroblast growth factor (FGF)

---

# 16. Chemokine Receptors

* [ ] CCR2
* [ ] CCR5
* [ ] CXCR3
* [ ] CXCR4
* [ ] CXCR5

---

# 17. Immune Checkpoint & Co-inhibitory Molecules (Expanded)

* [ ] VISTA
* [ ] B7-H3
* [ ] B7-H4
* [ ] BTLA
* [ ] Galectin-9

---

# 18. Specific Therapeutic Agents

## 18.1 Immune Checkpoint Inhibitors

* [ ] Nivolumab
* [ ] Pembrolizumab
* [ ] Atezolizumab
* [ ] Durvalumab
* [ ] Ipilimumab

## 18.2 Anti-angiogenic Agents

* [ ] Bevacizumab
* [ ] Sorafenib
* [ ] Lenvatinib
* [ ] Regorafenib

## 18.3 Cellular Therapy Components

* [ ] Chimeric antigen receptor (CAR) constructs
* [ ] Single-chain variable fragment (scFv)

---

# 19. Antigenic Targets in HCC & Solid Tumors

* [ ] Glypican-3 (GPC3)
* [ ] Alpha-fetoprotein (AFP)
* [ ] NY-ESO-1
* [ ] HER2
* [ ] EGFR

---

# 20. Genetic & Molecular Alterations

* [ ] TP53 mutation
* [ ] CTNNB1 mutation
* [ ] KRAS mutation
* [ ] BRAF mutation
* [ ] Microsatellite instability (MSI)

---

Below are **further entities** extracted from the three papers, expanding into additional categories not yet exhaustively enumerated. These include **immune subsets, metabolic regulators, intracellular mediators, stromal mediators, extracellular vesicle components, epigenetic regulators, additional biomarkers, and therapeutic concepts** documented across the texts   

Format preserved: **Markdown with checkboxes**, taxonomically grouped and non-duplicative relative to previous lists.

---

# 21. Additional Immune Cell Subsets

## 21.1 T Cell Functional States

* [ ] Exhausted T cells
* [ ] Memory T cells
* [ ] Effector memory T cells
* [ ] Central memory T cells
* [ ] Tissue-resident memory T cells (Trm)
* [ ] Anergic T cells

## 21.2 Myeloid Subpopulations

* [ ] Polymorphonuclear MDSCs (PMN-MDSCs)
* [ ] Monocytic MDSCs (M-MDSCs)
* [ ] Inflammatory monocytes
* [ ] Kupffer cells

## 21.3 Dendritic Cell Subsets

* [ ] Conventional dendritic cells (cDC1)
* [ ] Conventional dendritic cells (cDC2)
* [ ] Plasmacytoid dendritic cells (pDCs)

---

# 22. Additional Cytokines & Soluble Mediators

* [ ] IL-4
* [ ] IL-8
* [ ] IL-18
* [ ] IL-21
* [ ] IL-22
* [ ] IL-27
* [ ] IFN-α
* [ ] IFN-β
* [ ] Colony-stimulating factor 1 (CSF-1)
* [ ] Prostaglandin E2 (PGE2)
* [ ] Nitric oxide (NO)

---

# 23. Intracellular Signaling Molecules & Kinases

* [ ] AKT
* [ ] ERK1/2
* [ ] MEK
* [ ] mTOR
* [ ] PI3K
* [ ] JAK1
* [ ] JAK2
* [ ] SMAD2
* [ ] SMAD3
* [ ] SMAD4
* [ ] β-catenin

---

# 24. Epigenetic & Regulatory Factors

* [ ] DNA methyltransferases (DNMTs)
* [ ] Histone deacetylases (HDACs)
* [ ] MicroRNAs (miRNAs)
* [ ] Long non-coding RNAs (lncRNAs)

---

# 25. Additional Immune Modulatory Enzymes

* [ ] Tryptophan 2,3-dioxygenase (TDO)
* [ ] Ectonucleotidase CD39
* [ ] Ectonucleotidase CD73

---

# 26. Stromal & Matrix-Associated Molecules

* [ ] Tenascin-C
* [ ] Hyaluronic acid
* [ ] Fibroblast growth factor receptor (FGFR)
* [ ] Integrins
* [ ] Selectins

---

# 27. Extracellular Vesicles & Communication

* [ ] Exosomes
* [ ] Microvesicles
* [ ] Extracellular vesicles (EVs)

---

# 28. Additional Biomarkers & Diagnostic Indicators

* [ ] PD-L1 expression level
* [ ] Tumor mutational burden (TMB)
* [ ] Immune infiltration score
* [ ] AFP serum level
* [ ] Circulating tumor DNA (ctDNA)
* [ ] Circulating tumor cells (CTCs)

---

# 29. Resistance & Escape Mechanisms

* [ ] Immune checkpoint upregulation
* [ ] Antigen loss
* [ ] MHC downregulation
* [ ] T cell dysfunction
* [ ] Tumor heterogeneity
* [ ] Adaptive resistance
* [ ] Primary resistance

---

# 30. Therapeutic Strategy Concepts

* [ ] Combination immunotherapy
* [ ] Dual checkpoint blockade
* [ ] Adoptive T cell transfer
* [ ] Tumor-infiltrating lymphocyte (TIL) therapy
* [ ] Neoantigen vaccine
* [ ] Personalized immunotherapy
* [ ] Immune modulation therapy

---
To perform **sentence-level entity mining for maximal exhaustiveness**, I systematically expand entity coverage to include:

* All biological entities (cells, molecules, genes, proteins, receptors)
* All disease states and pathological mechanisms
* All therapeutic agents and modalities
* All biomarkers and measurable indicators
* All signaling intermediates
* All structural and microenvironmental components
* All mechanistic processes described at sentence granularity

Below is the **maximally expanded entity registry**, deduplicated and organized taxonomically. This reflects sentence-level conceptual extraction rather than summary-level abstraction.

---

# 1. Disease Entities

## 1.1 Primary Cancer Types

* [ ] Hepatocellular carcinoma (HCC)
* [ ] Solid tumors
* [ ] Colorectal carcinoma
* [ ] Non-small cell lung cancer
* [ ] Small cell lung cancer
* [ ] Breast carcinoma
* [ ] Pancreatic ductal adenocarcinoma
* [ ] Gastric carcinoma
* [ ] Prostate carcinoma
* [ ] Renal cell carcinoma
* [ ] Melanoma

## 1.2 Liver-Specific Conditions

* [ ] Liver cirrhosis
* [ ] Liver fibrosis
* [ ] Chronic liver inflammation
* [ ] Chronic hepatitis
* [ ] Viral hepatitis
* [ ] Hepatitis B infection
* [ ] Hepatitis C infection
* [ ] Non-alcoholic fatty liver disease (NAFLD)
* [ ] Non-alcoholic steatohepatitis (NASH)

---

# 2. Cellular Entities

## 2.1 Tumor Compartment

* [ ] Malignant hepatocytes
* [ ] Cancer stem cells
* [ ] Tumor progenitor cells

## 2.2 Adaptive Immune Cells

* [ ] CD4⁺ T lymphocytes
* [ ] CD8⁺ T lymphocytes
* [ ] Cytotoxic T lymphocytes (CTLs)
* [ ] Regulatory T cells (Tregs)
* [ ] Th1 cells
* [ ] Th2 cells
* [ ] Th17 cells
* [ ] T follicular helper cells
* [ ] Exhausted T cells
* [ ] Memory T cells
* [ ] Central memory T cells
* [ ] Effector memory T cells
* [ ] Tissue-resident memory T cells
* [ ] B lymphocytes
* [ ] Plasma cells

## 2.3 Innate Immune Cells

* [ ] Natural killer (NK) cells
* [ ] Natural killer T (NKT) cells
* [ ] Dendritic cells
* [ ] Conventional dendritic cells (cDC1)
* [ ] Conventional dendritic cells (cDC2)
* [ ] Plasmacytoid dendritic cells
* [ ] Tumor-associated macrophages (TAMs)
* [ ] M1 macrophages
* [ ] M2 macrophages
* [ ] Kupffer cells
* [ ] Myeloid-derived suppressor cells (MDSCs)
* [ ] Polymorphonuclear MDSCs
* [ ] Monocytic MDSCs
* [ ] Monocytes
* [ ] Neutrophils
* [ ] Cancer-associated neutrophils
* [ ] Mast cells

## 2.4 Stromal & Structural Cells

* [ ] Cancer-associated fibroblasts (CAFs)
* [ ] Hepatic stellate cells
* [ ] Endothelial cells
* [ ] Pericytes
* [ ] Mesenchymal stem cells

---

# 3. Surface Molecules & Receptors

## 3.1 T Cell Markers

* [ ] CD3
* [ ] CD4
* [ ] CD8
* [ ] CD25
* [ ] CD28
* [ ] CD40L
* [ ] ICOS
* [ ] OX40
* [ ] 4-1BB (CD137)

## 3.2 Myeloid Markers

* [ ] CD11b
* [ ] CD14
* [ ] CD33
* [ ] CD68
* [ ] CD80
* [ ] CD86
* [ ] CD163
* [ ] CD206

## 3.3 NK Markers

* [ ] CD56
* [ ] NKG2D
* [ ] NKp30
* [ ] NKp46

## 3.4 Adhesion Molecules

* [ ] ICAM-1
* [ ] VCAM-1
* [ ] Integrins
* [ ] Selectins

---

# 4. Immune Checkpoints & Co-Regulators

* [ ] PD-1
* [ ] PD-L1
* [ ] PD-L2
* [ ] CTLA-4
* [ ] LAG-3
* [ ] TIM-3
* [ ] TIGIT
* [ ] VISTA
* [ ] B7-H3
* [ ] B7-H4
* [ ] BTLA
* [ ] Galectin-9
* [ ] IDO
* [ ] TDO
* [ ] CD39
* [ ] CD73

---

# 5. Cytokines & Growth Factors

## 5.1 Interleukins

* [ ] IL-1
* [ ] IL-2
* [ ] IL-4
* [ ] IL-6
* [ ] IL-8
* [ ] IL-10
* [ ] IL-12
* [ ] IL-17
* [ ] IL-18
* [ ] IL-21
* [ ] IL-22
* [ ] IL-23
* [ ] IL-27

## 5.2 Other Cytokines

* [ ] TNF-α
* [ ] IFN-γ
* [ ] IFN-α
* [ ] IFN-β
* [ ] TGF-β
* [ ] GM-CSF
* [ ] CSF-1

## 5.3 Angiogenic & Mitogenic Factors

* [ ] VEGF-A
* [ ] VEGFR-2
* [ ] PDGF
* [ ] EGF
* [ ] HGF
* [ ] FGF
* [ ] FGFR

---

# 6. Intracellular Signaling Components

## 6.1 Kinases & Signaling Molecules

* [ ] PI3K
* [ ] AKT
* [ ] mTOR
* [ ] MEK
* [ ] ERK1/2
* [ ] JAK1
* [ ] JAK2
* [ ] STAT1
* [ ] STAT3
* [ ] STAT5
* [ ] SMAD2
* [ ] SMAD3
* [ ] SMAD4
* [ ] NF-κB
* [ ] β-catenin
* [ ] c-Myc

## 6.2 Pathways

* [ ] JAK/STAT pathway
* [ ] PI3K/AKT/mTOR pathway
* [ ] MAPK pathway
* [ ] NF-κB pathway
* [ ] Wnt/β-catenin pathway
* [ ] TGF-β signaling pathway
* [ ] VEGF signaling pathway

---

# 7. Metabolic & Hypoxia-Related Entities

* [ ] HIF-1α
* [ ] Lactate
* [ ] Adenosine
* [ ] Arginase-1
* [ ] iNOS
* [ ] Nitric oxide
* [ ] Reactive oxygen species
* [ ] GLUT1
* [ ] Prostaglandin E2

---

# 8. Extracellular Matrix & Structural Molecules

* [ ] Extracellular matrix
* [ ] Collagen
* [ ] Fibronectin
* [ ] Laminin
* [ ] Proteoglycans
* [ ] Hyaluronic acid
* [ ] Tenascin-C
* [ ] Matrix metalloproteinases
* [ ] MMP-2
* [ ] MMP-9

---

# 9. Genetic & Molecular Alterations

* [ ] TP53 mutation
* [ ] CTNNB1 mutation
* [ ] KRAS mutation
* [ ] BRAF mutation
* [ ] Microsatellite instability
* [ ] Tumor mutational burden

---

# 10. Tumor Antigens & Biomarkers

* [ ] Tumor-associated antigens
* [ ] Neoantigens
* [ ] Glypican-3
* [ ] Alpha-fetoprotein
* [ ] NY-ESO-1
* [ ] HER2
* [ ] EGFR
* [ ] PD-L1 expression
* [ ] Circulating tumor DNA
* [ ] Circulating tumor cells
* [ ] Immune infiltration score

---

# 11. Therapeutic Modalities & Agents

## 11.1 Checkpoint Inhibitors

* [ ] Nivolumab
* [ ] Pembrolizumab
* [ ] Atezolizumab
* [ ] Durvalumab
* [ ] Ipilimumab

## 11.2 Targeted & Anti-angiogenic Agents

* [ ] Bevacizumab
* [ ] Sorafenib
* [ ] Lenvatinib
* [ ] Regorafenib

## 11.3 Cellular Therapies

* [ ] CAR-T cells
* [ ] TCR-engineered T cells
* [ ] Adoptive cell transfer
* [ ] Tumor-infiltrating lymphocyte therapy

## 11.4 Vaccines & Viral Therapies

* [ ] Cancer vaccines
* [ ] Neoantigen vaccines
* [ ] Oncolytic viruses

---

# 12. Tumor Microenvironment Processes

* [ ] Immune evasion
* [ ] T cell exhaustion
* [ ] Immune suppression
* [ ] Angiogenesis
* [ ] Fibrogenesis
* [ ] Chronic inflammation
* [ ] Antigen presentation
* [ ] MHC downregulation
* [ ] Antigen loss
* [ ] Adaptive resistance
* [ ] Primary resistance
* [ ] Tumor heterogeneity

---
